OncoMatch/Clinical Trials/NCT03842943
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
Is NCT03842943 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Talimogene Laherparepvec for cutaneous melanoma.
Treatment: Pembrolizumab · Talimogene Laherparepvec — Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Allowed: BRAF mutation or wild-type allowed
BRAF mutant or wild type allowed (mutations status not necessary for enrollment)
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: oncolytic virus (T-VEC)
May not have been previously treated with T-VEC, any other oncolytic virus
Cannot have received: anti-PD-1 therapy (pembrolizumab)
May not have been previously treated with pembrolizumab, or any other PD-1, PD-L1, or PD-L2 inhibitor
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Louisville · Louisville, Kentucky
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify